top of page
Gotham__Org Gotham White.png
FKSI-10

Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version

For patients with Kidney Cancer, a 10 item scale

Overview

Overview

Below are the details for the FKSI-10 measure:

MEASURE NAME:

Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version (FKSI-10)

VERSION:

4

NUMBER OF ITEMS:

10

PATIENT POPULATION:

Kidney cancer patients 18 years and older

RECALL PERIOD:

Past 7 days

RESPONSE SCALE:

5 point Likert-type scale

DATA COLLECTION:

Paper and electronic

ADMINISTRATION:

Self-administration and interview when applicable

SUBSCALE DOMAINS:

Kidney cancer symptom index

TIME FOR COMPLETION:

Less than 5 minutes

SCORING:

Manual scoring template, some items are reverse scored. Total scores available.

RELATED MEASURES:

Language Availability

Available translations of the FKSI-10 can be obtained by registering for permission. Users are not permitted to translate the FKSI-10 without permission from FACIT.org. Permission from FACIT.org to translate the FKSI-10 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.

Please contact us for more information.

Language Availability
Licensing

Licensing

Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

Selected References

Selected References

Bukowski, R., Cella, D., Gondek, K., Escudier, B.  Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer.  American Journal of Clinical Oncology; 2007: 30(3): 220-227.  doi: 10.1097/01.coc.0000258732.80710.05.


Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J.  What are the most important symptom targets when treating advanced cancer?  A survey of providers in the National Comprehensive Cancer Network (NCCN).  Cancer Investigation 2003; 21(4): 526-535.  doi: 10.108/CNV-120022366.  


Cella, D., Yount, S., Du, H., Dhanda, R., Gondek, K., Langefeld, K., George, J., Bro, W., Kelly, C., & Bukowski, R.  Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).  Journal of Supportive Oncology 2006; 4(4):191-199.  


Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J.  Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.  Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. 


Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system.  Quality of Life Research 1996; 5: 309-320.


Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.


Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.


Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.

Related Measures

Related Measures

FKSI-15

Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version

NFKSI-19

National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version

FKSI-DRS

Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms

bottom of page